Bridgeway Capital Management LLC Sells 24,500 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Bridgeway Capital Management LLC reduced its stake in Prestige Consumer Healthcare Inc. by 26.3%, holding 68,500 shares worth approximately $5.89 million after selling 24,500 shares in the first quarter.
• Prestige Consumer Healthcare reported a net loss in earnings, with EPS of $0.95 for the last quarter, missing estimates by $0.06 and reflecting a 6.6% decline in revenue compared to the same period last year.
• The stock is currently rated as a "Moderate Buy" by analysts, with a consensus target price of $93.33, and a market capitalization of $3.28 billion.

Bridgeway Capital Management LLC lessened its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 26.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,500 shares of the company's stock after selling 24,500 shares during the quarter. Bridgeway Capital Management LLC owned approximately 0.14% of Prestige Consumer Healthcare worth $5,889,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Kayne Anderson Rudnick Investment Management LLC increased its position in Prestige Consumer Healthcare by 45.3% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock worth $135,903,000 after purchasing an additional 493,199 shares in the last quarter. Invesco Ltd. raised its position in shares of Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after purchasing an additional 261,537 shares in the last quarter. Congress Asset Management Co. raised its position in shares of Prestige Consumer Healthcare by 9.1% during the 1st quarter. Congress Asset Management Co. now owns 991,580 shares of the company's stock valued at $85,246,000 after acquiring an additional 82,838 shares in the last quarter. Westwood Holdings Group Inc. grew its stake in Prestige Consumer Healthcare by 7.1% during the 1st quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company's stock worth $74,044,000 after buying an additional 56,802 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Prestige Consumer Healthcare by 4.8% during the 1st quarter. Northern Trust Corp now owns 852,274 shares of the company's stock worth $73,270,000 after buying an additional 39,198 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH traded down $1.69 during trading on Friday, hitting $65.06. 693,488 shares of the stock were exchanged, compared to its average volume of 613,028. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 15.27, a price-to-earnings-growth ratio of 2.06 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a 1-year low of $62.95 and a 1-year high of $90.04. The company's fifty day simple moving average is $72.04 and its 200-day simple moving average is $79.86.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The business had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company's revenue for the quarter was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PBH shares. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Zacks Research lowered Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.